To find and disarm: Scientists develop platform to kill cancer cells

Google+ Pinterest LinkedIn Tumblr +

The new treatment will serve as both diagnosis and treatment of malignant tumours.

This breakthrough in the technologies of cancer diagnosis and treatment was made by an interdisciplinary Russian-German collaboration of chemists, physicists, and biologists from NUST MISIS, Lomonosov Moscow State University, Pirogov Russian National Research Medical University (RNRMU), and the University of Duisburg-Essen (Germany).

For the first time ever, scientists have shown that a hybrid nanomaterial based on magnetite-gold particles can serve as a universal platform to both detect cancer cells anywhere in the body and to complete targeted deliveries of drugs to these cells.

The discovery makes it possible to create and implement a completely new generation of cancer treatments in the coming years.

The results of this fundamental research conducted at the intersection of physics, chemistry, biology and medicine have been published in Scientific Reports.

“The interdisciplinary collaboration of scientists led by Maxim Abakumov, a Candidate of Chemical Sciences and the Head of the NUST MISIS Biomedical Nanomaterials Laboratory, has managed to develop a platform for simultaneous diagnosis and treatment of cancer. The aggregation of diagnosis and therapy at the cellular level — so-called theranostics — is now considered one of the most promising areas in modern medicine. Scientists now [have]to learn how to detect pathogenic cells at the earliest stage of the disease”, said Alevtina Chernikova, Rector of NUST MISIS.

If these pathogenic cells are tagged with magnetic nanoparticles, they can be diagnosed with the help of magnetic resonance imaging (MRI) and subsequently destroyed by either a drug or a magnetic field that heats and kills cancer cells.

“We have managed to combine gold (Au) and magnetite (Fe3O4) nanoparticles into a hybrid that has both magnetic properties and is capable of carrying the drug [to a tumour]. It turned out as a kind of ‘nanodumbbell’ which could become a platform — a universal base — of future theranostics, and we have shown that in our research”, said Maxim Abakumov, one of the project participants, assistant professor at RNRMU, and Head of the NUST MISIS Biomedical Nanomaterials Laboratory.

This manmade nanohybrid has been tested both in vitro and in vivo. Laboratory tests on mice with grafted tumours have already been completed.

“The article considers a model of a mouse breast tumour and shows the possibility to deliver the hybrid Fe3O4-Au particles to the tumour, loaded with the anti-tumour drug doxorubicin. The drug is released inside the tumour and has a therapeutic influence”, added Mariya Efremova, the project co-worker, junior research assistant at the Laboratory for Chemical Design of Bionanomaterials for Medical Applications at Lomonosov Moscow State University, and an engineer at the NUST MISIS Biomedical Nanomaterials Laboratory.

It is possible to place almost any drug (in place of doxorubicin) into the “nanodumbbell”, and this makes this hybrid an ideal platform to detect tumour cells and deliver drugs; previously proposed methods were only suitable for certain types of drugs and only worked on certain types of cancer cells.

Such versatility allows us to hope for the emergence of a new generation of treatments for malignant tumours in the coming years.

According to the most optimistic researchers on the project, it will be possible to proceed to pre-clinical trials in just two to three years time, as there is a few years’ of work remaining to be completed before clinical trials on real patients.

However, the concept of theranostics has still not been applied in clinical practice anywhere in the world, although Russian scientists are on the front lines of this area.

“As a scientific discipline, theranostics is now developing very quickly. The proposed platform demonstrates impressive and diverse effectiveness in lab conditions, however, it still has a long way [to go before getting]to patients”, said Marina Sekacheva, Head of the Center for Personalised Oncology “OncoTarget” at Sechenov University. Sekacheva believes that doctors should provide maximum practical support to fundamental scientists and continuously work with them on potentially groundbreaking projects such as this one.


Source: MISIS

Share.

About Author

ONA Editor

The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.

Leave A Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.